Intellia Therapeutics, Inc. (NTLA) Financial Statements
Industry: In Vitro & In Vivo Diagnostic Substances
In fiscal 2025, Intellia Therapeutics reported revenue of $67.7M, up 16.9% from $57.9M the year before. Net income was -$412.7M (a -609.9% net margin), or -$3.81 per diluted share. Operating margin was -651.7%. Operating activities generated -$394.7M of cash, leaving -$395.9M of free cash flow. At fiscal year end, Intellia Therapeutics held $842.1M in total assets against $170.7M in total liabilities, including $155.5M of cash and equivalents.
Open the full interactive Intellia Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Intellia Therapeutics Key Stats
| Share Price | $11.91 |
|---|---|
| Market Cap | $1.59B |
| Revenue YoY Growth | +16.9% |
| 52-Week Range | $8.04 – $27.98 |
| Shares Outstanding | 133.5 million (basic, 2026 Q2) |
Intellia Therapeutics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $58.0M | $33.1M | $52.1M | $36.3M | $57.9M | $67.7M |
| Cost of Goods Sold | $0 | $0 | — | — | — | — |
| Gross Profit | $58.0M | $33.1M | — | — | — | — |
| Operating Income | -$136.6M | -$267.9M | -$458.2M | -$515.3M | -$534.3M | -$441.0M |
| Pre-Tax Income | -$134.2M | -$267.9M | -$474.2M | -$481.2M | -$519.0M | -$412.7M |
| Income Tax | — | — | — | — | — | $0 |
| Net Income | -$134.2M | -$267.9M | -$474.2M | -$481.2M | -$519.0M | -$412.7M |
| Diluted EPS | -$2.40 | -$3.78 | -$6.16 | -$5.42 | -$5.25 | -$3.81 |
Intellia Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $13.8M | $23.0M | $15.0M | $7.7M |
| Net Income | -$101.3M | -$95.8M | -$96.2M | -$106.6M |
| Diluted EPS | -$0.92 | -$0.88 | -$0.81 | -$0.80 |
Intellia Therapeutics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $160.0M | $123.4M | $523.5M | $226.7M | $189.2M | $155.5M |
| Current Assets | $616.5M | $769.3M | $1.22B | $998.3M | $639.9M | $527.7M |
| Total Assets | $676.3M | $1.29B | $1.52B | $1.30B | $1.19B | $842.1M |
| Current Liabilities | $64.3M | $125.8M | $126.6M | $115.2M | $110.9M | $103.9M |
| Total Liabilities | $149.2M | $254.2M | $284.5M | $250.8M | $319.1M | $170.7M |
| Shareholders' Equity | $527.1M | $1.04B | $1.24B | $1.05B | $872.0M | $671.4M |
Intellia Therapeutics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$49.9M | -$225.0M | -$333.3M | -$394.1M | -$348.9M | -$394.7M |
| Cash From Investing | -$214.5M | -$550.8M | $160.3M | -$31.3M | $125.6M | $228.0M |
| Cash From Financing | $371.8M | $736.7M | $583.0M | $130.3M | $185.7M | $131.5M |
| Free Cash Flow | -$53.5M | -$237.8M | -$346.8M | -$408.1M | -$354.7M | -$395.9M |
Figures from Intellia Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Intellia Therapeutics financials page for every line item.
Intellia Therapeutics Company Profile
| Ticker | NTLA |
|---|---|
| Exchange | Nasdaq |
| Industry | In Vitro & In Vivo Diagnostic Substances |
| Headquarters | Cambridge, Massachusetts |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0001652130 |
Frequently Asked Questions
What was Intellia Therapeutics' revenue in fiscal 2025?
Intellia Therapeutics (NTLA) reported revenue of $67.7M for fiscal 2025.
What is Intellia Therapeutics' annual revenue history?
Intellia Therapeutics' annual revenue by fiscal year: 2020: $58.0M; 2021: $33.1M; 2022: $52.1M; 2023: $36.3M; 2024: $57.9M; 2025: $67.7M.
What was Intellia Therapeutics' net income in fiscal 2025?
Intellia Therapeutics reported net income of -$412.7M for fiscal 2025.
What was Intellia Therapeutics' earnings per share (EPS) in fiscal 2025?
Intellia Therapeutics' diluted EPS was -$3.81 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Intellia Therapeutics generate in fiscal 2025?
Intellia Therapeutics generated -$395.9M of free cash flow in fiscal 2025.
What was Intellia Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Intellia Therapeutics reported revenue of $7.7M.
How many shares of Intellia Therapeutics are outstanding?
Intellia Therapeutics reported a weighted average of 133.5 million basic shares outstanding in 2026 Q2.
What is Intellia Therapeutics' market cap?
Based on its latest closing price, Intellia Therapeutics (NTLA) has a market capitalization of about $1.59B.
When does Intellia Therapeutics' fiscal year end?
Intellia Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Intellia Therapeutics headquartered?
Intellia Therapeutics lists its business address in Cambridge, Massachusetts in its SEC filings.
Intellia Therapeutics Competitors & Similar Companies
See all 15 In Vitro & In Vivo Diagnostic Substances companies →